Tetraspan Injection 6%
Hydroxyethyl Starch · Sodium Chloride +5 more
Prescription medication · Combination
B. Braun Korea Co., Ltd.
MFDS item code 200903976 · Approved 2009.06.08
This product's status changed to Approval withdrawn on 2023.07.26. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Rapid isovolemic hemodilution; treatment and prevention of hypovolemia
This medication is used for the treatment and prevention of reduced blood volume when alternative therapies are inappropriate. It is also utilized in acute normovolemic hemodilution (ANH), a rapid volume replacement hemodilution technique. This helps safely and effectively improve the patient's condition in these situations.
1. Administer by intravenous infusion, and administer the initial 10~20mL slowly while carefully observing the patient (possibility of an anaphylactoid reaction). 2. The daily dose and infusion rate are determined according to the patient's blood loss, maintenance or restoration of hemodynamic parameters, and hemodilution. Depending on the patient's condition, administration may be repeated for several days. The duration of administration is determined according to the duration and degree of the reduction in blood volume, the hemodynamic effects, and hemodilution. However, the maximum daily dose is 50 mL per kg of body weight.
This medication may increase the risk of mortality, kidney damage, and excessive bleeding, and should only be used when other treatment options are not appropriate. It should not be used in patients with sepsis, kidney damage, or serious conditions. When administering this medication to patients with hypovolemia, careful evaluation of the risk of kidney damage or liver dysfunction should be undertaken, and if possible, alternative fluids should be prioritized. Calcium-containing intravenous preparations should not be administered simultaneously using the same infusion apparatus due to the potential for precipitation; infusion lines must be thoroughly cleaned if used. It should not be given to patients with specific conditions such as sepsis, severe liver disease, fluid overload, renal failure, heart failure, blood coagulation disorders, dehydration, receiving dialysis, intracranial hemorrhage, severe hypernatremia or hyperchloremia, or to patients allergic to this medication's components. Care must be taken with newborns, especially as there are risks associated with concomitant use of calcium-containing products. Dose adjustment and careful administration are necessary for patients with a history of liver disease, blood coagulation disorders, severe dehydration, and impaired kidney or liver function. During the administration of this medication, allergic reactions may occur, and patients should be closely monitored; if any abnormal symptoms arise, administration should be stopped immediately and emergency care sought. In addition, this medication may affect blood coagulation and may result in side effects such as vomiting, chills, fever, and headache. In cases of overdose, circulatory burden may occur, so dosage should be adjusted in heart failure patients, and electrolyte and fluid status as well as kidney function should be monitored regularly during administration. This medication should not be mixed with other drugs, and unused contents should be discarded immediately after opening. During pregnancy, the risks to the fetus and treatment efficacy should be considered carefully, and caution is advised during breastfeeding due to insufficient safety data. This medication can interfere with the diagnosis of pancreatitis in blood tests, so careful attention is required in interpreting test results. Overdose can lead to circulatory overload, such as pulmonary edema, and if these symptoms arise, administration should be stopped and appropriate treatment should be received. Finally, this medication should only be used for intravenous injection, kept out of reach of children, stored below 25 degrees Celsius, and not frozen.
Anaphylactic reaction, influenza-like symptoms, bradycardia, tachycardia, bronchospasm, non-cardiogenic pulmonary edema, rash, itching, pruritus, vomiting, chills, fever, headache, increased serum α-amylase concentration, coagulation mechanism abnormalities, decreased hematocrit, decreased plasma protein concentration, decreased red blood cell volume, prolonged bleeding time, increased activated partial thromboplastin time, decreased FⅧ/vWF complex levels
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container and kept at room temperature between 1 degree and 30 degrees Celsius, ensuring that it does not freeze. Thus, it is important to avoid excessively cold or hot places and to maintain an appropriate temperature.
A colorless to pale yellow transparent solution in a colorless transparent polyethylene container or colorless transparent plastic bag (Nexcel Pharmaceutical Film M312) used for injection.
Bag - 500 milliliters/bag
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Hydroxyethyl Starch · Sodium Chloride +5 more
Prescription medication · Combination
B. Braun Korea Co., Ltd.
Hydroxyethyl Starch · Sodium Chloride +5 more
Prescription medication · Combination
B. Braun Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.